Silence Therapeutics Stock Target Price and Analyst Consensus
| SLN Stock | USD 6.60 0.15 2.33% |
The current analyst and expert consensus on Silence Therapeutics is Strong Buy, with 3 strong buy opinions. The current projected Silence Therapeutics target price consensus is 39.53 with 6 analyst opinions. Check out Macroaxis Advice on Silence Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Silence Therapeutics PLC analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Silence Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Silence Therapeutics. We strongly encourage you to use your own analysis of Silence Therapeutics PLC to validate this buy or sell advice. Silence Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Silence Therapeutics PLC target price to derive its highest and lowest estimates based on projected price volatility of 6.293.
Lowest Forecast 35.97 | Highest Forecast 43.88 | Target Price 39.53 |
Silence |
It's important to approach Silence Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Silence Therapeutics price targets
Silence Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Silence Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Silence Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Silence Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Silence Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Silence Therapeutics is a key component of Silence Therapeutics valuation and have some predictive power on the future returns of a Silence Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested over 40 shares | |
 | Hedge Favorites Invested over 50 shares | |
 | Power Assets Invested over 200 shares | |
 | Macroaxis Index Invested few shares | |
 | Cash Cows Invested few shares | |
 | Impulse Invested few shares | |
 | FinTech Invested few shares | |
 | Technology Invested few shares | |
 | Millennials Best Invested few shares | |
Check out Macroaxis Advice on Silence Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.